Insulin and leptin levels in obese patients with and without breast cancer
Maria del Socorro Romero-Figueroa1, José de Jesús Garduño-García, Jesús Duarte-Mote
1Coordinación de Investigación en Salud, Delegación Estado de México Poniente, Instituto Mexicano del Seguro Social, Toluca, México.
Background:
Leptin has been associated with progression and poor survival in BC. Moreover, it is still controversial as to whether the effect of leptin depends only on its correlation with body mass index (BMI), or could be a direct role of adipokine in the development of BC. The aim of this study was to identify if there was a difference between serum leptin levels and insulin in obese patients with and without BC.
Patients And Methods:
A cross-sectional study was made in 156 women, a group of 78 with obesity and BC and 78 with obesity without BC. When subjects agreed to participate, written informed consent was obtained from all subjects. Biochemical variables such as glucose, triglycerides, high-density and low-density lipoprotein, cholesterol, insulin, and leptin were measured and homeostasis model assessment (HOMA-IR) was calculated.
Results:
The age, number of parities, glucose, HOMA-IR, and leptin were significantly different at P < .05.
Conclusion:
Serum leptin levels and leptin/BMI ratio were statistically significantly increased in patients with BC.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity
Psychoneuroimmunology: Diabetes and Cancer
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug Dosing: Obese Patients


